Last reviewed · How we verify
NCT06689917
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
NA trial testing JY231 Injection in B-ALL in 20 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Tongji Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 20 January 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- JY231 Injection
Conditions studied
Sponsor
Tongji Hospital
Who can join
Adults 18 to 75, any sex, with B-ALL or B-NHL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies.
Chen Y, Xin Q, Qiu J, Zhu M, et al · · 2025 · cited 8× · PMID 41250215 · DOI 10.1186/s40164-025-00725-5 -
In vivo CAR cell therapy: from bench to bedside.
Xu J, Chen Z, Su L, Ren A, et al · · 2025 · cited 7× · PMID 41261423 · DOI 10.1186/s13045-025-01759-2
Verify or expand the search:
- PubMed search for NCT06689917
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of JY231 Injection
Trials testing the same drug.
- NCT06902025 — JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia · NA · not yet recruiting
- NCT06887985 — JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs) · NA · not yet recruiting
- NCT06797024 — JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders · NA · recruiting
- NCT06678282 — JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia · NA · recruiting
Other recruiting trials for B-ALL
Currently open trials in the same condition.
- NCT06785324 — Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL) · NA · recruiting
- NCT07244406 — Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL · Phase 2 · recruiting
- NCT06911710 — The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors · Phase 1, PHASE2 · recruiting
- NCT06678282 — JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia · NA · recruiting
- NCT04781634 — a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL · Phase 1, PHASE2 · recruiting
Other Tongji Hospital trials
Trials by the same sponsor.
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
- NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
- NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06689917 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
- Last refreshed: 8 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06689917.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing